Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (647)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01639703 | Hepatic Xenetix-CT Perfusion | completed | Phase 4 | 96 | GuerbetINDUSTRY | 4 | Jul 13, 2017 | clinicaltrials |
| NCT01639352 | Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 20 | Lynn FeunOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01456156 |
| completed |
| N/A |
| 76 |
| Chinese Academy of Medical SciencesOTHER |
| 1 |
| Jul 5, 2017 |
| clinicaltrials |
| NCT03208335 | Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC) | unknown | Phase 2 | 61 | Chinese PLA General HospitalOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma(ZIPANG) | completed | Phase 2 | 167 | Zeria PharmaceuticalINDUSTRY | 3 | Jul 2, 2017 | clinicaltrials |
| NCT02644603 | Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer | unknown | N/A | 214 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT03198975 | Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma | unknown | — | 40 | Ming KuangOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | completed | Phase 1 | 16 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT03197155 | Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence(RECAR) | completed | — | 68 | Hospices Civils de LyonOTHER | 0 | Jun 23, 2017 | clinicaltrials |
| NCT01393093 | Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas(TACE-KMG) | unknown | N/A | 2,840 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | completed | — | 131 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jun 8, 2017 | clinicaltrials |
| NCT03178929 | Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma | unknown | N/A | 207 | Beijing Insight Science & Technology Co. Ltd.OTHER | 0 | Jun 7, 2017 | clinicaltrials |
| NCT03178409 | Combined HCC-MFCCC | completed | — | 100 | University of MilanOTHER | 0 | Jun 6, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01673802 | The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma | completed | Early Phase 1 | 18 | University of Alabama at BirminghamOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT03081637 | FLNA in HCC Patients | completed | — | 115 | University of MilanOTHER | 0 | Jun 1, 2017 | clinicaltrials |
| NCT00911196 | Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma | completed | — | 200 | GlaxoSmithKlineINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03166436 | RFA for Malignant Biliary Obstruction | unknown | N/A | 140 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | May 30, 2017 | clinicaltrials |
| NCT02705118 | Evaluation of Performance of Automatic Fusion for Radiofrequency Ablation of Hepatocellular Carcinoma(FAME-US) | completed | N/A | 82 | JOON-IL CHOIOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer | terminated | N/A | 29 | Weill Medical College of Cornell UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03161925 | Chinese Liver Cancer Clinical Survey(CLCS) | unknown | — | 5,000 | Beijing Insight Science & Technology Co. Ltd.OTHER | 0 | May 22, 2017 | clinicaltrials |
| NCT03163186 | Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).(ACCESS) | completed | — | 55 | Medical University of South CarolinaOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT01673269 | Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD | completed | N/A | 60 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01595217 | MRCP Diagnoses EHCC Better When Combined DWI | completed | N/A | 99 | China Medical University, ChinaOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT02550613 | Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00366457 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT03114085 | Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 170 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | terminated | N/A | 5 | University of Alabama at BirminghamOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | terminated | Phase 1 | 33 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT02093104 | TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)(TACE) | completed | — | 40 | University of British ColumbiaOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03140007 | Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .(Cholangioscopy) | unknown | N/A | 60 | Asian Institute of Gastroenterology, IndiaOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study(PET/MRCP) | withdrawn | — | 0 | University of TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT03138239 | The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG | unknown | N/A | 16 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | May 3, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT01034865 | Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer | completed | — | 750 | Stanford UniversityOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT01357486 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis(PRODIGE 21) | completed | Phase 2 | 160 | University Hospital, BordeauxOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | terminated | — | 117 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01481805 | Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients | completed | — | 100 | Samsung Medical CenterOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02420678 | Quality of Life in Patients With Hepatocellular Carcinoma | unknown | — | 300 | Asan Medical CenterOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT03130712 | A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | unknown | Phase 1 / Phase 2 | 10 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Apr 26, 2017 | clinicaltrials |
| NCT02725996 | By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy | unknown | Phase 2 | 140 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jul 13, 2017source: clinicaltrials